Packaging Requirements: Original Artwork Only, No Photocopies or Overlaid Labels

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Packaging is a formal requisite of Guatemalan registration: Article 5.1.10 of NT 37 Versión 5-2016 requires the submission of the original or a readable mock-up of the primary and/or secondary packaging, and states expressly that photocopies are not accepted, nor are overlaid labels. Sealed samples are submitted under Article 5.1.11, with quantities determined according to the list of quantities issued by the National Health Laboratory (LNS), and only when applicable. The same requirement carries through the change procedures — Articles 6.1.4, 6.2.4, 6.10.3, 6.11.3 and 6.12.4 all reiterate that photocopies are not accepted. Taken together, these provisions make packaging a continuous obligation that follows the product from the first filing through every subsequent variation, and a manufacturer who treats it as a one-off submission task will encounter the same refusal at each change window.

  • Packaging must be submitted as the original or a readable mock-up; photocopies and overlaid labels are expressly excluded.
  • Sealed samples follow the LNS quantity list and are required only when applicable.
  • Sample quantities are fixed by the LNS list, not chosen by the applicant.
  • Multiple change clauses restate the no-photocopy rule for packaging.
  • Whether samples are needed at all depends on the risk class determined under Annex 1.
  • Spanish-language instructions for use and warnings must appear on the packaging itself or on formal mock-ups.

2. Legal basis

The table below collects the clauses that govern packaging across registration and change procedures. Read as a group, they show that the standard treats packaging as a formal requisite whose form of presentation — original or readable mock-up, never a photocopy — is as decisive as its content.

DocumentClauseContent
NT 37, Versión 5-2016 (2016-02-22)Article 5.1.10Original or readable mock-up of primary and/or secondary packaging; photocopies and overlaid labels not accepted
NT 37, Versión 5-2016Article 5.1.11Sealed samples (according to the LNS quantity list), submitted when applicable
NT 37, Versión 5-2016Articles 6.1.4 / 6.2.4 / 6.11.3 / 6.12.4Change procedures likewise do not accept photocopies of packaging
NT 37, Versión 5-2016Article 6.10.3A change of primary packaging requires submission of the new material specifications
NT 37, Versión 5-2016Article 7Minimum content requirements for packaging labelling
NT 37, Versión 5-2016Annex 1The risk class determines whether testing is required, and with it whether samples are required

3. Expert insights

Insight one: the rejection of overlaid labels closes the door on improvised packaging changes. The phrase “etiquetas sobrepuestas” in the clause refers to labels affixed on top of the original packaging. Read together with Article 7.1.2 — which requires that instructions for use and warnings of imported products appear in Spanish on the packaging — the operational conclusion is that the authority will not accept a Spanish-language sticker added after the fact to satisfy the language duty. The Spanish information must be embodied in the packaging itself or in the formal mock-up submitted for review. This is why the two provisions function as a pair: one defines the language obligation, and the other forecloses the shortcut of meeting it with an overlaid label.

Insight two: the packaging requirement runs through registration and every change procedure. Under Article 6, multiple change items — change of holder, change of manufacturer name, change of product name, change of packaging or specifications, and addition of an alternate manufacturing site — list packaging as a distinct document item, each restating that photocopies are not accepted. Packaging management is therefore a continuous obligation across the product lifecycle, not a single submission act performed once at registration. Companies that keep an always-current packaging master file, aligned with the version approved for the registration, move through change windows without scrambling for artwork at the last minute.

Insight three: sample quantities are decided by the LNS list, not by the applicant. Article 5.1.11 states that sealed samples are presented “según listado de cantidades de LNS” — according to the LNS quantity list. The applicant must prepare samples in the quantities the LNS list prescribes; deciding the quantity unilaterally risks either a shortfall that stalls the laboratory schedule or an excess that wastes product. Because the sample count feeds directly into testing logistics, confirming the applicable quantities before the samples are pulled is a simple step that prevents downstream scheduling friction.

Insight four: the sample obligation is bound to the risk class. Annex 1 makes Class I exempt from testing, while Classes II to IV require physicochemical and microbiological testing. Whether samples are needed therefore depends on whether the classification decision has been settled. Preparing samples before the class is fixed wastes resources if the product turns out to be exempt, and if the class is determined wrongly the sample specifications themselves will be wrong. The practical order is always: classify first, then sample.

4. Practical recommendations

  • Prepare packaging as originals or formal readable mock-ups, and exclude photocopies and overlaid-label samples in every case.
  • Build the Spanish instructions for use and warnings into the packaging itself or the formal mock-up, never as stickers added afterwards.
  • Wait until the classification decision is settled before preparing samples, and then draw them strictly to the LNS quantity list.
  • For change procedures, prepare packaging in step with the filing and check the corresponding clause to confirm whether packaging stands as a distinct document item.
  • Self-audit packaging content item by item against Article 7, including batch number, expiry date, registration number and, where applicable, the word “Estéril”.

5. Verification checklist

  • □ Packaging is submitted as the original or a readable mock-up
  • □ No photocopies and no overlaid labels are present in the dossier
  • □ Spanish instructions for use and warnings are embodied in the packaging itself
  • □ The classification decision has been settled
  • □ Sample quantities have been checked against the LNS list
  • □ Packaging content has been self-audited item by item against Article 7

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Guatemalan market. Our team manages Ministry of Public Health and Social Assistance (MSPAS) registrations, coordinates import and distributor requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail